Rational Approach to Stable, Universal Somatostatin Analogues with Superior Therapeutic Potential

The unique pharmacological effects mediated by SRIF-14 [1] are derived from its universal high affinity binding to all somatostatin receptor subtypes sst1–5. Until now, somatostatin analogues used in the clinic have exhibited high affinity binding only to sst2 and sst5. The goal of this research was to discover a small, stable SRIF mimic exhibiting universal high affinity binding to sst1–5.